Literature DB >> 21671179

Leptin activates STAT3 and ERK1/2 pathways and induces endometrial cancer cell proliferation.

Yi Liu1, Liqun Lv2, Wei Xiao2, Cheng Gong2, Jie Yin2, Donghua Wang2, Hui Sheng2.   

Abstract

Obesity is an established risk factor for endometrial cancer. Leptin, a secreted protein of the ob gene by white adipose tissue, plays an important role in the regulation of food intake and energy consumption in the brain and acts as a potential growth stimulator in normal and neoplastic cancer cells. However, a direct role for leptin in endometrial cancer has not been demonstrated. In the present study, the effect of leptin on the proliferation of Ishikawa endometrial cancer cells was investigated as well as the possible mechanism(s) underlying this action in endometrial cancers which express both short and long isoforms of leptin receptors. The expression of leptin receptor (ObRb) in Ishikawa cells was detected by RT-PCR and Western blotting. The cells after serum starvation, were treated by leptin with various concentrations (0, 10, 50, 100, 150 ng/mL) for different durations (6, 12, 24 h). The effect of leptin treatment on cell proliferation was examined by MTT assay. Meanwhile, inhibitory effect of Janus tyrosine kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) inhibitor AG490 or extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor PD98059 on the proliferation of Ishikawa cells induced by leptin was also studied. Ishikawa cells were treated with 100 ng/mL leptin for various periods (0, 20, 40, 60 min), and the levels of STAT3 phosphorylation and ERK1/2 phosphorylation were examined by Western blotting. The results showed that leptin induced the phosphorylation of STAT3 and the activation of ERK1/2 in a time- and dose-dependent manner in the Ishikawa endometrial cancer cells. Blocking STAT3 phosphorylation with the inhibitor AG490, or blocking ERK1/2 activation by the specific ERK1/2 kinase inhibitor, PD98059, abolished leptin-induced proliferation of Ishikawa cells. In addition, leptin was found to potently induce the invasion of endometrial cancer cells in a Matrigel invasion assay. Leptin-stimulated invasion was effectively blocked by pharmacological inhibitors of STAT3 (AG490) and ERK1/2 kinase (PD98059). These results suggested that leptin promotes endometrial cancer growth and invasiveness by activating STAT3 and ERK1/2 signaling pathways and therefore blocking its action at the receptor level can be a rational therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671179     DOI: 10.1007/s11596-011-0382-7

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  41 in total

Review 1.  Leptin is a growth factor in cancer.

Authors:  Ponnandai Somasundar; David W McFadden; Stanley M Hileman; Linda Vona-Davis
Journal:  J Surg Res       Date:  2004-02       Impact factor: 2.192

Review 2.  Obesity and cancer.

Authors:  J P Deslypere
Journal:  Metabolism       Date:  1995-09       Impact factor: 8.694

3.  Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a.

Authors:  Sandrine Giraud; Frédéric Bienvenu; Sylvie Avril; Hugues Gascan; David M Heery; Olivier Coqueret
Journal:  J Biol Chem       Date:  2001-12-31       Impact factor: 5.157

4.  Leptin and body mass index in relation to endometrial cancer risk.

Authors:  Eleni Petridou; Maria Belechri; Nick Dessypris; Panagiotis Koukoulomatis; Emmanuel Diakomanolis; Evangelos Spanos; Dimitrios Trichopoulos
Journal:  Ann Nutr Metab       Date:  2002       Impact factor: 3.374

Review 5.  Obesity, adipocytokines, and insulin resistance in breast cancer.

Authors:  D P Rose; D Komninou; G D Stephenson
Journal:  Obes Rev       Date:  2004-08       Impact factor: 9.213

6.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

7.  Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer.

Authors:  Mariusz Koda; Mariola Sulkowska; Andrzej Wincewicz; Luiza Kanczuga-Koda; Boguslaw Musiatowicz; Magdalena Szymanska; Stanislaw Sulkowski
Journal:  Ann N Y Acad Sci       Date:  2007-01       Impact factor: 5.691

Review 8.  Leptin signaling.

Authors:  Rexford S Ahima; Suzette Y Osei
Journal:  Physiol Behav       Date:  2004-04

9.  Prostate cancer cell proliferation is influenced by leptin.

Authors:  Ponnandai Somasundar; Krista A Frankenberry; Heath Skinner; Giridhar Vedula; David W McFadden; Dale Riggs; Barbara Jackson; Reyna Vangilder; Stanley M Hileman; Linda C Vona-Davis
Journal:  J Surg Res       Date:  2004-05-01       Impact factor: 2.192

10.  STAT3 is required for the gp130-mediated full activation of the c-myc gene.

Authors:  N Kiuchi; K Nakajima; M Ichiba; T Fukada; M Narimatsu; K Mizuno; M Hibi; T Hirano
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

View more
  18 in total

1.  Dose-dependent biphasic leptin-induced proliferation is caused by non-specific IL-6/NF-κB pathway activation in human myometrial cells.

Authors:  Marina Barrichon; Tarik Hadi; Maeva Wendremaire; Clémentine Ptasinski; Renaud Seigneuric; Guillaume Marcion; Marc Delignette; Jacques Marchet; Monique Dumas; Paul Sagot; Marc Bardou; Carmen Garrido; Frédéric Lirussi
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

2.  An exploratory investigation of links between changes in adipokines and quality of life in individuals undergoing weight loss interventions: possible implications for cancer research.

Authors:  Faina Linkov; Lora E Burke; Marina Komaroff; Robert P Edwards; Anna Lokshin; Mindi A Styn; Eugene Tseytlin; Kyle E Freese; Dana H Bovbjerg
Journal:  Gynecol Oncol       Date:  2014-01-22       Impact factor: 5.482

Review 3.  Molecular pathways: adiponectin and leptin signaling in cancer.

Authors:  Michael N Vansaun
Journal:  Clin Cancer Res       Date:  2013-01-25       Impact factor: 12.531

4.  Leptin promotes proliferation of neonatal mouse stem/progenitor spermatogonia.

Authors:  Nilgün Yersal; Sevil Köse; Utku Horzum; Sinan Özkavukcu; Kyle E Orwig; Petek Korkusuz
Journal:  J Assist Reprod Genet       Date:  2020-08-25       Impact factor: 3.412

5.  The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.

Authors:  Hye Sook Chon; Douglas C Marchion; Yin Xiong; Ning Chen; Elona Bicaku; Xiaomang Ba Stickles; Nadim Bou Zgheib; Patricia L Judson; Ardeshir Hakam; Jesus Gonzalez-Bosquet; Robert M Wenham; Sachin M Apte; Johnathan M Lancaster
Journal:  Gynecol Oncol       Date:  2011-10-26       Impact factor: 5.482

6.  Leptin promotes glioblastoma.

Authors:  Johnathan E Lawrence; Nicholas J Cook; Richard A Rovin; Robert J Winn
Journal:  Neurol Res Int       Date:  2012-01-04

7.  The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes.

Authors:  Francesca Capone; Eliana Guerriero; Giovanni Colonna; Patrizia Maio; Alessandra Mangia; Raffaele Marfella; Giuseppe Paolisso; Francesco Izzo; Nicoletta Potenza; Luigi Tomeo; Giuseppe Castello; Susan Costantini
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

8.  Systematic Analysis of Endometrial Cancer-Associated Hub Proteins Based on Text Mining.

Authors:  Huiqiao Gao; Zhenyu Zhang
Journal:  Biomed Res Int       Date:  2015-08-23       Impact factor: 3.411

9.  Modulation of the leptin receptor mediates tumor growth and migration of pancreatic cancer cells.

Authors:  Alisha M Mendonsa; Madeleine C Chalfant; Lee D Gorden; Michael N VanSaun
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

10.  Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial.

Authors:  V Seebacher; G Hofstetter; S Polterauer; A Reinthaller; C Grimm; R Schwameis; S Taucher; A Wagener; C Marth; N Concin
Journal:  Br J Cancer       Date:  2013-06-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.